Form 4: OrbiMed Advisors Sells Passage Bio Shares in Multiple Transactions

OrbiMed Advisors LLC, a significant shareholder of Passage Bio, Inc., has sold a portion of its common stock holdings in a series of transactions between January 10 and January 14, 2025.

Summary

• OrbiMed Advisors LLC, along with related entities, disposed of Passage Bio, Inc. (PASG) common stock between January 10 and January 14, 2025.
• The sales were executed at varying prices, with weighted average sale prices ranging from $0.58 to $0.70 per share.
• On January 10, 2025, 126,209 shares were sold at $0.66.
• On January 13, 2025, 17,986 shares were sold at $0.64.
• On January 14, 2025, 79,024 shares were sold at $0.60.
• Following these transactions, OrbiMed's indirect beneficial ownership stands at 7,034,626 shares.
• The shares are held by OrbiMed Private Investments VII, LP (OPI VII), with OrbiMed Capital GP VII LLC (GP VII) as the general partner and OrbiMed Advisors LLC as the managing member of GP VII.
• OrbiMed Advisors disclaims beneficial ownership except to the extent of its pecuniary interest.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the sale of shares by a major shareholder, which can be interpreted as a lack of confidence in the company's future performance. The disclaimer of beneficial ownership further contributes to the negative sentiment.

Negatives

• OrbiMed Advisors, a significant shareholder, reduced its stake in Passage Bio through a series of sales.

Risks

• Continued selling pressure from major shareholders like OrbiMed could negatively impact the stock price.
• The disclaimer of beneficial ownership by OrbiMed Advisors and GP VII, except for pecuniary interest, introduces uncertainty regarding their long-term commitment to Passage Bio.

Industry Context

Form 4 filings are standard disclosures for significant shareholders and insiders, providing transparency into their trading activities. The size and frequency of these transactions can influence investor sentiment and stock price, particularly for smaller-cap companies like Passage Bio.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement, making direct comparison straightforward in terms of compliance.
• However, the impact of these sales is specific to Passage Bio's stock dynamics and investor base.
• Similar sales by large shareholders in comparable biotech companies (e.g., those with similar market caps and therapeutic focus) could be used to gauge the potential market reaction.

Stakeholder Impact

• Shareholders may experience a decrease in stock value due to the selling pressure.
• The company's reputation could be affected if the sales are perceived negatively by the market.

Key Dates